Clinical Trial

TMS for Exposure Therapy Resistant OCD

Study acronym: TETRO
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
TETRO is a multi-center placebo-controlled double-blind randomized controlled trial with an intervention phase of 5-7 weeks and a follow-up phase of 12 months in 250 adult (18 years and older) OCD patients who show no/insufficient response to ERP, aiming to establish the cost-effectiveness of low frequency (1 Hz) rTMS to the pre-SMA (compared to sham rTMS to the pre-SMA) as adjuvant treatment to exposure with response prevention (ERP). The treatment consists of 4 times/week rTMS combined with ERP for at least 5 weeks (20 sessions), with optional extension phase of 1 or 2 weeks (maximum of 28 sessions in total).
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2022-04-15; most recent amendment 2026-03-01.
Status change: Not Yet Recruiting → Recruiting 2022-05-15
Trial Details
NCT Number NCT05331937
Lead Sponsor Amsterdam UMC, location VUmc
Collaborators: GGZ inGeest, Radboud University Medical Center, ProPersona, Maastricht University Medical Center, Mondriaan, Neurocare
Conditions 1 Hz Real rTMS to the Pre-SMA, 1 Hz Sham rTMS to the Pre-SMA
Enrollment 250 participants
Start Date 2022-05-16
Primary Completion 2027-12-01 (estimated)
Study Completion 2027-12-01 (estimated)
Updated on ClinicalTrials.gov 2026-03-04